ライフサイエンスコーパス: atherectomy

1 of estrogen and intervention (angioplasty or atherectomy).

2 s for intervention lesion preparation (e.g., atherectomy).

3 additional treatment (balloon angioplasty or atherectomy).

4 utcomes for patients treated with rotational atherectomy.

5 roposed to be predictive of restenosis after atherectomy.

6 malities associated with rotational coronary atherectomy.

7 nt risk factor for restenosis after coronary atherectomy.

8 atherectomy and adjunct directional coronary atherectomy.

9 45 +/- 87 degrees after directional coronary atherectomy.

10 tervention, particularly in those undergoing atherectomy.

11 of restenosis after coronary angioplasty and atherectomy.

12 atherectomy and adjunct directional coronary atherectomy.

13 lected from patients undergoing percutaneous atherectomy.

14 onary angiography performed six months after atherectomy.

15 ing technologies, intravascular imaging, and atherectomy.

16 coronary calcifications and higher usage of atherectomy.

17 ug-eluting stents (DES), covered stents, and atherectomy.

18 nderwent PTCA, laser ablation, or rotational atherectomy.

19 ronary atherectomy and high speed rotational atherectomy.

20 gioplasty, laser ablation, and/or rotational atherectomy.

21 coronary angioplasty or directional coronary atherectomy.

22 rotic lesions were obtained from directional atherectomy.

23 duced platelet aggregation during rotational atherectomy.

24 the changes in the application of rotational atherectomy.

25 excimer laser (0.89 [0.29-2.7]), rotational atherectomy (0.96 [0.53-1.7]), and vascular brachytherap

26 ts (10 904 PTA; 11 295 stent placement; 4422 atherectomy; 10 239 surgical bypass), all-cause mortalit

27 n-Q wave myocardial infarctions by 71% after atherectomy (15.4% for placebo vs. 4.5% for bolus and in

28 oon angioplasty (73% vs. 50%) and rotational atherectomy (16.1% vs. 8.3%) were used more often in sma

29 treatment included stents (50%), directional atherectomy (24%), and balloon angioplasty (20%).

30 - 16%, p < 0.001) and lower after rotational atherectomy (27 +/- 15%, p < 0.001).

31 to stents (18.5% vs. 41.9%) and directional atherectomy (3.7% vs. 13.5%), conventional balloon angio

32 for adjunctive angioplasty after extraction atherectomy (37 +/- 16%, p < 0.001) and excimer laser an

33 -cause mortality over 4 years was 49.3% with atherectomy, 51.4% with surgical bypass, 53.7% with sten

34 amputation rates over 4 years were 6.8% with atherectomy, 7.8% with stent placement, 8.1% with PTA, a

35 fuse lesions, underwent balloon angioplasty, atherectomy, additional stenting, or a combination of th

36 4 [95% CI, 1.06-1.23]) with no difference in atherectomy (adjusted odds ratio, 0.98 [95% CI, 0.91-1.0

37 ific stenoses, but the ability of rotational atherectomy alone to optimize lumen dimensions in large

38 y 10% of these procedures include rotational atherectomy, although the national average rate of stent

39 PAR-4 expression was increased in carotid atherectomies and saphenous vein specimens from diabetic

40 ed (1) human lesions obtained by directional atherectomy and (2) experimentally induced neointima for

41 (97.1%) of 1120 lesions assigned to orbital atherectomy and 1068 (97.0%) of 1101 lesions assigned to

42 ectomy than in those treated with rotational atherectomy and adjunct balloon angioplasty.

43 son with 208 lesions treated with rotational atherectomy and adjunct coronary angioplasty was perform

44 lesions in 163 patients by use of rotational atherectomy and adjunct directional coronary atherectomy

45 mmediate and long-term results of rotational atherectomy and adjunct directional coronary atherectomy

46 Rotablator atherectomy and adjunctive PTCA significantly improve di

47 od flow velocity before and after Rotablator atherectomy and after adjunctive percutaneous translumin

48 evaluated 22 patients undergoing rotational atherectomy and compared their wall motion abnormalities

49 the mechanisms by which rotational coronary atherectomy and coronary angioplasty produce their effec

50 synergistic relationship between rotational atherectomy and directional coronary atherectomy in the

51 was lower in lesions treated with rotational atherectomy and directional coronary atherectomy than in

52 ptotic cell death has been reported in human atherectomy and endarterectomy specimens and for neointi

53 Rotational atherectomy, extraction atherectomy and excimer laser angioplasty can facilitate

54 gioplasty was also observed after extraction atherectomy and excimer laser angioplasty for ostial les

55 unctive balloon angioplasty after rotational atherectomy and excimer laser angioplasty provides bette

56 alities are common after rotational coronary atherectomy and have a longer duration than those observ

57 d, which includes PTCA, directional coronary atherectomy and high speed rotational atherectomy.

58 The combination of rotational atherectomy and intra-coronary stent placement is betwee

59 w and dedicated technologies such as orbital atherectomy and intravascular lithotripsy, as well as th

60 angioplasty is often used immediately after atherectomy and laser angioplasty to further enlarge lum

61 chanical interventions, with advancements in atherectomy and lithotripsy techniques improving outcome

62 directional (n = 19) and rotational (n = 6) atherectomy and stent implantation (n = 11).

63 eviews the existing literature on rotational atherectomy and stent implantation for complex lesions a

64 ularization of ULMT is required, directional atherectomy and stenting appear to be the preferred tech

65 grees to 166 +/- 93 degrees after rotational atherectomy and to 145 +/- 87 degrees after directional

66 coronary angioplasty or directional coronary atherectomy and whose peak CK levels did not exceed twic

67 coprotein IIb/IIIa inhibitor; none underwent atherectomy, and all had final TIMI 3 flow.

68 ess likely to use intracoronary diagnostics, atherectomy, and radial access.

69 y angioplasty, laser angioplasty, rotational atherectomy, and/or stent implantation.

70 Mechanical thrombectomy and atherectomy are efficient methods of arterial recanaliza

71 ic total occlusions or debulking plaque with atherectomy are less rigorously studied and have niche r

72 30 human peripheral arteries by directional atherectomy at times ranging from 13 days to 36 months a

73 tients with 90 lesions underwent directional atherectomy before coronary stenting.

74 Routine treatment with orbital atherectomy before drug-eluting stent implantation did n

75 othesis that plaque removal with directional atherectomy before stent implantation may lower the inte

76 Rotational atherectomy burr time was longer in the patients who dev

77 ) have demonstrated modest benefits favoring atherectomy but at a cost of increased acute ischemic co

78 igh-risk coronary angioplasty or directional atherectomy but increases bleeding complications.

79 curs commonly after coronary angioplasty and atherectomy, but the causes of restenosis are poorly und

80 Adjunctive coronary atherectomy (CA) can be utilized in treating severely ca

81 und analysis to determine whether rotational atherectomy causes ablation of non-calcified atheroscler

82 he hypothesis that more aggressive "optimal" atherectomy could be performed safely to produce larger

83 (PEB) angioplasty, stenting, and directional atherectomy (DA) have provided new options for the treat

84 s to evaluate the performance of directional atherectomy (DA) plus DCB angioplasty versus DCB alone i

85 Vessel preparation with directional atherectomy (DA) potentially improves outcomes of DCB.

86 16 patients undergoing directional coronary atherectomy (DCA) and control samples from the internal

87 ious clinical trials of directional coronary atherectomy (DCA) have failed to show significant improv

88 in patients treated by directional coronary atherectomy (DCA) in the Coronary Angioplasty Versus Exc

89 EAT-I demonstrated that directional coronary atherectomy (DCA) resulted in higher rates of early comp

90 Directional coronary atherectomy (DCA) specimens from 63 lesions were analyze

91 Previous directional coronary atherectomy (DCA) trials have shown no significant reduc

92 ss serial changes after directional coronary atherectomy (DCA).

93 sms of restenosis after directional coronary atherectomy (DCA).

94 Optimal DCA was defined as using a 7F atherectomy device and adjunctive PTCA if necessary to a

95 minimally invasive technique, the Silverhawk Atherectomy device.

96 tment methods for resistant lesions, such as atherectomy devices and cutting balloons.

97 Although atherectomy devices have been used to treat bifurcation

98 ng stents; excisional, laser, and rotational atherectomy devices; devices for crossing total occlusio

99 eroablative therapies by laser or mechanical atherectomy, drug-coated balloons, vascular brachytherap

100 Rotational atherectomy effectively ablates noncalcified plaque in n

101 onary angioplasty, directional or rotational atherectomy, excimer laser angioplasty, or Palmaz-Schatz

102 Rotational atherectomy, extraction atherectomy and excimer laser an

103 METHODS AND DEFINITIVE AR study (Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to I

104 Directional atherectomy followed by coronary stenting could be perfo

105 TEC atherectomy followed by immediate Palmaz-Schatz coronary

106 dural, hospital and clinical outcomes of TEC atherectomy followed by immediate Palmaz-Schatz coronary

107 ss of transluminal extraction catheter (TEC) atherectomy followed by immediate Palmaz-Schatz coronary

108 laser angioplasty, rotational or directional atherectomy followed by stenting, whereas 106 patients w

109 recruited 89 patients who underwent coronary atherectomy for de novo atherosclerosis (n=55) or in-ste

110 ted facilitated angioplasty after rotational atherectomy for ostial, eccentric, ulcerated and calcifi

111 20 patients undergoing directional coronary atherectomy for stable angina were analyzed for immunore

112 ive patients undergoing directional coronary atherectomy for symptomatic coronary artery disease.

113 ssue specimens were retrieved by directional atherectomy from 10 patients in whom in-stent restenosis

114 ery) retrieved by using directional coronary atherectomy from 25 patients at 0.5 to 23 (mean, 5.7) mo

115 Samples acquired by directional coronary atherectomy from 25 patients with type 2 diabetes and 18

116 urred in 113 of 1008 patients in the orbital atherectomy group (1-year target vessel failure 11.5% [9

117 ry of baseline wall motion in the rotational atherectomy group (153 min, 95% confidence interval [CI]

118 276 patients with 286 lesions in the orbital atherectomy group and 279 patients with 292 lesions in t

119 627 (62.2%) of 1008 patients in the orbital atherectomy group and 619 (62.1%) of 997 in the balloon

120 tion was 7.67 mm(2) (SD 2.27) in the orbital atherectomy group and 7.42 mm(2) (2.54) in the balloon a

121 curred in 39 of 1008 patients in the orbital atherectomy group and in 26 of 997 in the balloon angiop

122 on was significantly lower in the rotational atherectomy group than in the coronary angioplasty group

123 Patients undergoing directional atherectomy had a lower baseline risk for acute complica

124 sions that develop restenosis after coronary atherectomy have more macrophages and smooth muscle cell

125 used in 9% of procedures, laser in 30%, and atherectomy in 16%, and thrombolytic therapy was adminis

126 15% and before stenting in 43%), directional atherectomy in 4% and angioplasty alone in 7%.

127 patients (alone in 30% and after rotational atherectomy in 43%), rotational atherectomy in 58% (alon

128 r rotational atherectomy in 43%), rotational atherectomy in 58% (alone in 15% and before stenting in

129 ver, after changes in reimbursement, PVI and atherectomy in outpatient facilities and office-based cl

130 farction, in patients undergoing directional atherectomy in the Evaluation of c7E3 for the Prevention

131 2,099 patients who underwent angioplasty or atherectomy in the Evaluation of IIb/IIIa platelet recep

132 ational atherectomy and directional coronary atherectomy in the treatment of calcific lesions.

133 coronary angioplasty (PTCA) (with or without atherectomy) in the side branch, and Gp 2 included 54 pa

134 The use of atherectomy increased 2-fold in outpatient hospital sett

135 use of intravascular imaging and rotational atherectomy increased significantly through the study pe

136 esion revascularization was a larger overall atherectomy index (84% vs. 59%, p = 0.048).

137 tients with high anatomic complexity and use atherectomy, intracoronary diagnostics, and mechanical s

138 Rotational atherectomy is a safe and feasible technique for treatme

139 Rotational atherectomy is best suited for treating calcific stenose

140 Rotational atherectomy is currently the preferred treatment for hea

141 rials of balloon angioplasty versus coronary atherectomy, laser angioplasty, or cutting balloon ather

142 techniques such as directional or rotational atherectomy, laser angioplasty, or thrombectomy devices

143 te the randomized controlled experience with atherectomy, laser, or atherotomy versus balloon angiopl

144 After adjunct directional coronary atherectomy, lumen area increased even more to 6.7 +/- 2

145 TEC atherectomy may reduce distal embolization, and stenting

146 lesions alone (n = 541) or after extraction atherectomy (n = 277), rotational atherectomy (Rotablato

147 andomized to vessel preparation with orbital atherectomy (OA) versus balloon angioplasty (BA) before

148 ocedural and clinical outcomes after orbital atherectomy (OA) versus intravascular lithotripsy (IVL)-

149 was the performance of directional coronary atherectomy (odds ratio, 4.1; P < .0001), followed by th

150 or without stenting, laser angioplasty, and atherectomy of the femoral, popliteal, and tibial vessel

151 We evaluated the effects of orbital atherectomy on intraluminal paclitaxel delivery to human

152 VSMCs were derived from coronary atherectomies or from normal coronary arteries from tran

153 assigned to lesion preparation with orbital atherectomy or balloon angioplasty (997 with 1242 lesion

154 ions were randomly assigned (1:1) to orbital atherectomy or balloon angioplasty before PCI with drug-

155 ed stents), with or without adjunct therapy (atherectomy or intravascular lithotripsy).

156 vals, 1.21-1.96; P<0.001), use of rotational atherectomy (OR, 2.37; 95% confidence intervals, 1.80-3.

157 nary angioplasty, laser ablation, rotational atherectomy, or additional stenting (36% of lesions).

158 directional coronary atherectomy, rotational atherectomy, or excimer laser angioplasty.

159 ficiaries who received PTA, stent placement, atherectomy, or surgical bypass for critical limb ischem

160 sluminal angioplasty (PTA), stent placement, atherectomy, or surgical bypass in patients diagnosed wi

161 diagnosis who received PTA, stent placement, atherectomy, or surgical bypass.

162 1 SD) to 3.9 +/- 1.1 mm(2) after rotational atherectomy, owing to a decrease in plaque plus media ar

163 Treatment with atherectomy plus PTCA resulted in lower postprocedure re

164 or debulking (with rotational or directional atherectomy) plus adjunctive PTCA (n = 40).

165 ross all types of PVI, whereas mean costs of atherectomy procedures in outpatient and office-based cl

166 l safety and long-term results of rotational atherectomy (RA) followed by low-pressure balloon dilata

167 Rotational atherectomy (RA) is an established tool in interventiona

168 Rotational atherectomy (RA) is an important interventional tool for

169 oronary angioplasty (ELCA) versus rotational atherectomy (RA), both followed by adjunct PTCA; 119 pat

170 angioplasty (BA), repeat stent or rotational atherectomy (RA).

171 n the coronary angioplasty group (rotational atherectomy rate constant 0.069 +/- 0.079/min vs. corona

172 Directional atherectomy-related non-Q wave myocardial infarction app

173 sound Restenosis (SURE) Trial and in Optimal Atherectomy Restenosis Study (OARS) were enrolled in thi

174 ultrasound (IVUS) substudy of OARS (Optimal Atherectomy Restenosis Study) was designed to assess the

175 Since Rotablator atherectomy results in luminal enlargement by plaque pul

176 t and early patients treated with rotational atherectomy revealed an increase in the complexity of pa

177 g to the treatment strategy: CBA, rotational atherectomy (ROTA), additional stenting (STENT), and per

178 extraction atherectomy (n = 277), rotational atherectomy (Rotablator) (n = 211) or excimer laser angi

179 l coronary angioplasty, directional coronary atherectomy, rotational atherectomy, or excimer laser an

180 substantially less u-PA were present in the atherectomy samples from subjects with diabetes.

181 All human coronary atherectomy samples stained positive for Ang II and macr

182 ed in microvessels in the human aorta and in atherectomy samples.

183 om 1.310-3.450 pmol/micromol phospholipid in atherectomy specimens compared with 0.045-0.115 pmol/mic

184 t binds specifically to HA was used to stain atherectomy specimens from 29 human restenotic lesions (

185 A total of 47 coronary atherectomy specimens from patients with diabetes mellit

186 mellitus were examined and compared with 48 atherectomy specimens from patients without diabetes.

187 This study of atherectomy specimens investigated the in vivo role of L

188 Immunohistochemical studies on human atherectomy specimens revealed the presence of fVIII in

189 Coronary atherectomy specimens were definitely positive in 66 (73

190 Eighteen coronary atherectomy specimens with restenosis after PTCA from pa

191 ients with DM were compared with 18 coronary atherectomy specimens with restenosis after PTCA from pa

192 V) DNA is present in restenotic lesions from atherectomy specimens.

193 andomized Stent Implantation, Postrotational Atherectomy (SPORT) trial.

194 angioplasty, stent deployment or rotational atherectomy strategies.

195 of each artery was treated using an orbital atherectomy system (OAS) under simulated blood flow and

196 s well as the optimization of the rotational atherectomy system, has increased operators' confidence

197 ational atherectomy and directional coronary atherectomy than in those treated with rotational athere

198 After atherectomy, the mean (+/- SD) minimal luminal diameter

199 After rotational atherectomy, the minimal lumen cross-sectional area incr

200 on of the 2015 EAPCI consensus on rotational atherectomy, the number of percutaneous coronary interve

201 tion abnormalities after rotational coronary atherectomy, the prevalence and duration of these wall m

202 Macrophages are increased in coronary atherectomy tissue from primary lesions that develop res

203 ed on trichrome-stained sections of coronary atherectomy tissue.

204 sing both cultured human CASMCs and coronary atherectomy tissues, we studied the roles of osteopontin

205 The Balloon vs Optimal Atherectomy Trial (BOAT) was conducted to evaluate wheth

206 n the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT) I and II studies.

207 first Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) influenced subsequent pract

208 n the Coronary Angioplasty Versus Excisional Atherectomy Trial with angiographic follow-up were conta

209 s, severe coronary calcification, and higher atherectomy usage, yet CKD was not associated with a hig

210 wave myocardial infarction with directional atherectomy use compared with PTCA.

211 c occlusive disease intervention, rotational atherectomy use, number of stents, hypertension, and fem

212 Atherectomy, used independently or adjunctively, was not

213 ents were imaged before and after rotational atherectomy using intravascular ultrasound systems incor

214 r Severe Calcific Coronary Arteries: Orbital Atherectomy Versus Conventional Angioplasty Technique Be

215 tudy used pre-rotational and post-rotational atherectomy volumetric intravascular ultrasound analysis

216 ([mean +/- SD] 10.3 +/- 6 min for rotational atherectomy vs. 9.6 +/- 4.2 min for coronary angioplasty

217 Directional coronary atherectomy was associated with a larger acute gain in b

218 Stand-alone atherectomy was attempted, and adjunct therapy was used

219 Debulking with excimer laser or atherectomy was performed in 133 patients (139 lesions)

220 intervention in the EPIC trial, directional atherectomy was performed in 197 (10%).

221 Before atherectomy was performed, we measured blood levels of a

222 90 symptomatic patients undergoing coronary atherectomy were tested for the presence of Chlamydia sp

223 Women undergoing atherectomy who received estrogen had a significantly lo

224 We aimed to prospectively compare orbital atherectomy with a balloon angioplasty-based strategy be

225 We compared an early registry of rotational atherectomy with a recent registry to examine the evolut

226 in patients undergoing directional coronary atherectomy with a variety of control specimens and comp

227 r the treatment of true bifurcation lesions, atherectomy with adjunctive PTCA is safe, improves acute

228 Directional atherectomy with deep arterial wall resection as practic

229 Randomized trials comparing directional atherectomy with percutaneous transluminal coronary angi

230 Rotational atherectomy with the Rotablator catheter has improved pe

231 ndergoing balloon angioplasty or directional atherectomy within 72 h of presentation with either unst